Search

To analyze the expression of CCR7 and Tim-3 in childhood patients with acute lymphoblastic leukemia (ALL) and their predictive value for prognosis.Eighty-six newly diagnosed ALL childhood patients from January 2007 to January 2017 treated in our hospital were selected. The expression level of CCR7 and Tim-3 in bone marrow isolated cells of ALL patients were detected by flow cytometry, all the patients were divided into the recurrence group and non-recurrence group according to the follow-up results, the differences in the expressions of CCR7, Tim-3 between the two groups were compared. The correlation between the expression of CCR7 , Tim-3 and the clinicopathologic features of ALL patients were analyzed, the predictive value of CCR7 and Tim-3 for the prognosis of newly ALL patients were evaluated by ROC curve, and the relationship between serum CCR7, Tim-3 and prognosis were analyzed.The expression levels of CCR7 and Tim-3 in recurrence group were significantly higher than those in non-recurrence group(P0.05). The critical value of CCR7 for diagnosis of recurrence was 45.97%, the sensitivity was 66.7%, the specificity was the 84.5% and the area under ROC curve (AUC) was 0.798 (95CI 0.777-0.939). The critical value of Tim-3 for diagnosis of recurrence was 53.54%, the sensitivity was 73.3%, the specificity was the 80.3% and the AUC was 0.806 (95CI 0.792-0.947). The AUC of the combined detection of CCR7 and Tim-3 was 0.895 (95CI 0.914-0.996), sensitivity 86.6%, specificity 78.9% (P0.05); There was no significant correlation between CCR7, Tim-3 expression and age, sex, hemoglobin concentration, number of white blood cells, bone marrow blasts, platelets, central nervous system invasion, fusion gene (P0.05). The exogenous infiltration rate of patients with high expression of CCR7 and Tim-3 was significantly higher than those in low expression group (P005). The high expression rate 76.9% of Tim-3 in patients with T-ALL was significantly higher than that of B-ALL patients with Tim-3 high expression rate 45.2% (P0.05). The median OS of patients with CCR7 level ≥45.97% and45.97% were 9.3 months and 13.6 months respectively(P=0.004), and the Tim-3≥53.54% and Tim-353.54% were 9.1 months and 13.6 months respectively(P=0.001). The results of Cox's multi-factor regression analysis showed that CCR7 level(HR=1.024, 95 CI 1.001-1.049) and Tim-3 level (HR=1.879, 95 CI 1.183- 2.985) were the independent risk factors that affect the OS in ALL patients(P0.05).The expression of CCR7 and Tim-3 in bone marrow isolated cells of ALL patients shows good predictive value for prognosis, and the combination of CCR7 and Tim-3 can improve the sensitivity of the detection, the higher expression of CCR7 and Tim-3 can be used as potential indexes in prognosis evaluate.CCR7与Tim-3在儿童急性淋巴细胞白血病中的表达及其联合检测对预后评估的价值.探讨趋化因子受体7（CCR7）与T细胞免疫球蛋白粘液素-3（Tim-3）在儿童急性淋巴细胞白血病(ALL)中的表达及其联合检测对预后评估的价值.选取本院2007年1月至2017年1月期间收治的初治ALL患者86例，采用流式细胞仪检测入组对象的骨髓分离细胞中CCR7、Tim-3表达水平，根据随访结果分为复发组和非复发组，比较2组CCR7、Tim-3表达差异，分析CCR7、Tim-3的表达与ALL患者临床病理特征的相关性，采用ROC曲线评价CCR7、Tim-3对初治ALL患者的评估预测价值，分析ALL患者 CCR7、Tim-3表达与预后的关系.复发组CCR7与Tim-3表达水平明显高于非复发组（P＜0.05）；CCR7诊断的临界值为45.97%,其对应的灵敏度为66.7%，特异度为84.5%，ROC曲线下面积分别为0.798（95 CI 0.777-0.939）；Tim-3诊断的临界值为53.54%，其对应的灵敏度为73.3%，特异度为80.3%，ROC曲线下面积分别为0.806（95 CI 0.792-0.947）；联合诊断ROC曲线下面积分别为0.895（95 CI 0.914-0.996），对应的灵敏度86.6%，特异度78.9%（P＜0.05)；CCR7、Tim-3表达与年龄、性别、血红蛋白浓度、白细胞数、骨髓中原始细胞数、血小板计数、中枢神经系统侵袭、细胞遗传学融合基因无明显相关性（P＞0.05）；CCR7、Tim-3高表达患者髓外浸润率明显高于低表达组（P＜0.05）；T-ALL患者Tim-3高表达率(76.9%)明显高于B-ALL患者Tim-3高表达率(45.2%)（P＜0.05）；CCR7≥45.97%及45.97%患者中位OS时间分别为9.3个月、13.6个月（P=0.004）。Tim-3≥ 53.54%及Tim-353.54%患者的中位OS时间分别为9.1个月、13.6个月（P=0.001）。COX多因素回归分析结果显示，CCR7（HR=1.024， 95 CI 1.000-1.049）及Tim-3（HR=1.879， 95 CI 1.183-2.985）水平为影响ALL患者OS的独立危险因素（P＜0.05）.急性淋巴细胞白血病儿童初诊骨髓细胞中CCR7、Tim-3表达对于疾病预后具有良好的预测价值，二者联合检测能够提升检测的灵敏度，CCR7、Tim-3高表达与OS密切相关，可以作为评估ALL预后的潜在指标.

Cell division cycle 42 (CDC42), which is a member of the Rho GTPase family, has been reported to regulate the metastasis of various human cancer cells; however, the role of CDC42 in gastric cancer (GC) remains unclear. The present study aimed to investigate the effects of CDC42 on the proliferation, migration and invasion of GC. Furthermore, the molecular mechanisms underlying the effects of CDC42 on GC were explored. The expression levels of CDC42 in the AGS and SGC7901 human GC cell lines were reduced by RNA interference. Knockdown of CDC42 significantly inhibited the proliferation of AGS and SGC7901 cells, and it was suggested that this inhibitory process may be due to cell cycle arrest at G1/S phase and downregulation of cyclin A, cyclin D1, cyclin E and proliferating cell nuclear antigen. Furthermore, knockdown of CDC42 markedly inhibited the migration and invasion of GC cells, and suppressed the expression of matrix metalloproteinase 9. These results indicated that CDC42 is a key regulator involved in regulating the proliferation, migration and invasion of GC, and it may be considered a potential therapeutic target in GC.

AIM: To investigate the relationship between Interleukin-8 (IL-8) and proliferation, adhesion, migration, invasion and chemosensitivity of gastric cancer (GC) cells. METHODS: The IL-8 cDNA was stably transfected into human GC cell line MKN-45 and selected IL-8-secreting transfectants. The expression of IL-8 in human GC cell line KATO-III was inhibited by RNA interference. The expressions of mRNA and protein of IL-8 in GC cells were detected by real-time reverse transcription-polymerase chain reaction or enzyme-linked immunosorbent assay (ELISA). RESULTS: The overexpression of IL-8 resulted in an increased cell adhesion, migration and invasion, and a significant resistance to oxaliplatin in MKN-45 cells. Inhibition of IL-8 expression with small interfering RNA decreased the adhesion, migration and invasion functions and oxaliplatin resistance in KATO-III cells. IL-8 increased NF-κB and Akt activities and adhesion molecules ICAM-1, VCAM-1, and CD44 expression in GC cells. CONCLUSION: Overexpression of IL-8 promotes the adhesion, migration, invasion, and chemoresistance of GC cells, indicating that IL-8 is an important therapeutic target in GC.